A report commissioned by the Dutch government says that treatments which cost > €80 000 for every extra quality-adjusted life year should not be covered

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1550, 2006-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Limitations of the Methods Used for Calculating Quality-Adjusted Life-Year Values

By Duru G.  

PharmacoEconomics, Vol. 20, Iss. 7, 2002-01 ,pp. : 463-473

Adis International

Access to resources Recommend Favorite

Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective

By Bobinac Ana   van Exel N. J. A.   Rutten Frans F. H.   Brouwer Werner B. F.  

Value in Health, Vol. 13, Iss. 8, 2010-12 ,pp. : 1046-1055

Blackwell Publishing

Access to resources Recommend Favorite

The techniques used as a basis from which to calculate quality-adjusted life-years (QALYs) are flawed

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 370, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

By Cremieux P-Y.  

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 459-472

Adis International

Access to resources Recommend Favorite

Estimation of Burden of Lead for Offspring of Female Lead Workers: A Quality-Adjusted Life Year (QALY) Assessment

By Chuang Hung-Yi   Chao Kun-Yu   Wang Jung-Der  

Journal of Toxicology and Environmental Health, Vol. 68, Iss. 17-18, 2005-09 ,pp. : 1485-1496

Taylor & Francis Ltd

Access to resources Recommend Favorite